TNFRSF8 and systemic sclerosis: In areas such as autoimmune diseases, the CD30-targeting BV has brought initial clinical benefits for SSc, while studies on agents like ABBV-3373 have suggested the potential of ADCs to deliver immunomodulators and reduce systemic side effects in chronic immune diseases such as RA and SLE.